Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy

Abstract

Effective anticancer therapy can be achieved by designing a targeted drug-delivery system with high stability during circulation and efficient uptake by the target tumour cancer cells. We report here a novel nano-assembled drug-delivery system, formed by multivalent host-guest interactions between a polymer-cyclodextrin conjugate and a polymer-paclitaxel conjugate. The multivalent inclusion complexes confer high stability to the nano-assembly, which efficiently delivers paclitaxel into the targeted cancer cells via both passive and active targeting mechanisms. The ester linkages between paclitaxel and the polymer backbone permit efficient release of paclitaxel within the cell by degradation. This novel targeted nano-assembly exhibits significant antitumour activity in a mouse tumour model. The strategy established in this study also provides knowledge for the development of advanced anticancer drug delivery.

A new target ligand Ser–Glu for PEPT1-overexpressing cancer imaging

“…Furthermore, ex vivo fluorescence imaging of excised normal organs and tumors from mice euthanized at 32 hours post-injection revealed obvious differences between NPs-DIP and NPs groups in NPs biodistribution ( Figure 5C). With the calculation methods reported previously, 30 significantly increased NPs accumulation in the tumor site was discovered for NPs-DIP compared with NPs. Meanwhile, varying degrees of decreased accumulation of NPs in normal organs were found in the NPs-DIP group in contrast to the NPs group ( Figure 5D).…”

Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer

“…4AeB) indicated complete elimination of the Z group from PLL. The degree of polymerization (20) of PLL was quantified from the peak integration ratio of hexylamine (eCH 3 , 0.79 ppm) to the a-carbon proton of PLL (eCHe, 4.42 ppm) ( Supplementary Fig. 1).…”

Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells

“…Although peptides usually have weaker binding affinity and stability than antibodies, they generally have more efficient tissue penetration ability due to smaller size, and multimeric labeling of peptides onto nanocarriers may improve their binding avidity and stability [13][14][15]. In support of this, IL4RPep-1 has been exploited as a targeting ligand on drug-loaded nanocarriers and successfully enhanced drug delivery to tumors [16][17][18][19].…”